| Azacitidine and venetoclax in previously untreated acute myeloid leukemia CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei, ... New England Journal of Medicine 383 (7), 617-629, 2020 | 1968 | 2020 |
| Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia CD DiNardo, K Pratz, V Pullarkat, BA Jonas, M Arellano, PS Becker, ... Blood, The Journal of the American Society of Hematology 133 (1), 7-17, 2019 | 1709 | 2019 |
| Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label … CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei, M Thirman, ... The lancet oncology 19 (2), 216-228, 2018 | 728 | 2018 |
| Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial JE Cortes, S Khaled, G Martinelli, AE Perl, S Ganguly, N Russell, ... The Lancet Oncology 20 (7), 984-997, 2019 | 457 | 2019 |
| How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia BA Jonas, DA Pollyea Leukemia 33 (12), 2795-2804, 2019 | 166 | 2019 |
| Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow‐up from a phase 1b study DA Pollyea, K Pratz, A Letai, BA Jonas, AH Wei, V Pullarkat, M Konopleva, ... American journal of hematology 96 (2), 208-217, 2021 | 130 | 2021 |
| Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine KW Pratz, BA Jonas, V Pullarkat, C Recher, AC Schuh, MJ Thirman, ... Journal of Clinical Oncology 40 (8), 855-865, 2022 | 118 | 2022 |
| SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways BA Jonas, ML Privalsky Journal of Biological Chemistry 279 (52), 54676-54686, 2004 | 112 | 2004 |
| NCCN Guidelines® insights: myelodysplastic syndromes, version 3.2022: featured updates to the NCCN guidelines PL Greenberg, RM Stone, A Al-Kali, JM Bennett, U Borate, AM Brunner, ... Journal of the National Comprehensive Cancer Network 20 (2), 106-117, 2022 | 86 | 2022 |
| Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia BC Medeiros, SM Chan, NG Daver, BA Jonas, DA Pollyea American journal of hematology 94 (7), 803-811, 2019 | 85 | 2019 |
| Corepressors: custom tailoring and alterations while you wait M Goodson, BA Jonas, MA Privalsky Nuclear receptor signaling 3 (1), nrs. 03003, 2005 | 82 | 2005 |
| Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine DA Pollyea, KW Pratz, AH Wei, V Pullarkat, BA Jonas, C Recher, S Babu, ... Clinical Cancer Research 28 (24), 5272-5279, 2022 | 81 | 2022 |
| Alternative mRNA splicing of SMRT creates functional diversity by generating corepressor isoforms with different affinities for different nuclear receptors ML Goodson, BA Jonas, ML Privalsky Journal of Biological Chemistry 280 (9), 7493-7503, 2005 | 77 | 2005 |
| MDS prognostic scoring systems–past, present, and future BA Jonas, PL Greenberg Best Practice & Research Clinical Haematology 28 (1), 3-13, 2015 | 75 | 2015 |
| Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial JM Watts, MR Baer, J Yang, T Prebet, S Lee, GJ Schiller, SN Dinner, ... The Lancet Haematology 10 (1), e46-e58, 2023 | 71 | 2023 |
| Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia DJ DeAngelo, BA Jonas, JL Liesveld, DL Bixby, AS Advani, P Marlton, ... Blood, The Journal of the American Society of Hematology 139 (8), 1135-1146, 2022 | 71 | 2022 |
| A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are≥ to 65 … C DiNardo, D Pollyea, K Pratz, MJ Thirman, A Letai, M Frattini, B Jonas, ... Blood 126 (23), 327, 2015 | 69 | 2015 |
| Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients≥ 65 years ineligible for standard induction therapy. DA Pollyea, CD Dinardo, MJ Thirman, A Letai, AH Wei, BA Jonas, ... Journal of Clinical Oncology 34 (15_suppl), 7009-7009, 2016 | 59 | 2016 |
| Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology DA Pollyea, JK Altman, R Assi, D Bixby, AT Fathi, JM Foran, I Gojo, ... Journal of the National Comprehensive Cancer Network 21 (5), 503-513, 2023 | 56 | 2023 |
| Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia G Ho, BA Jonas, Q Li, A Brunson, T Wun, THM Keegan British journal of haematology 177 (5), 791-799, 2017 | 56 | 2017 |
Aaron S RosenbergUniversity of California, Davis School of Medicine在 ucdavis.edu 的电子邮件经过验证
